Literature DB >> 33739374

Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination.

Venkata Viswanadh Edara1, William H Hudson2, Xuping Xie3, Rafi Ahmed2, Mehul S Suthar1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33739374      PMCID: PMC7980146          DOI: 10.1001/jama.2021.4388

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  6 in total

1.  Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies.

Authors:  Abigail Vanderheiden; Venkata Viswanadh Edara; Katharine Floyd; Robert C Kauffman; Grace Mantus; Evan Anderson; Nadine Rouphael; Sri Edupuganti; Pei-Yong Shi; Vineet D Menachery; Jens Wrammert; Mehul S Suthar
Journal:  Curr Protoc Immunol       Date:  2020-12

2.  An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.

Authors:  Lisa A Jackson; Evan J Anderson; Nadine G Rouphael; Paul C Roberts; Mamodikoe Makhene; Rhea N Coler; Michele P McCullough; James D Chappell; Mark R Denison; Laura J Stevens; Andrea J Pruijssers; Adrian McDermott; Britta Flach; Nicole A Doria-Rose; Kizzmekia S Corbett; Kaitlyn M Morabito; Sijy O'Dell; Stephen D Schmidt; Phillip A Swanson; Marcelino Padilla; John R Mascola; Kathleen M Neuzil; Hamilton Bennett; Wellington Sun; Etza Peters; Mat Makowski; Jim Albert; Kaitlyn Cross; Wendy Buchanan; Rhonda Pikaart-Tautges; Julie E Ledgerwood; Barney S Graham; John H Beigel
Journal:  N Engl J Med       Date:  2020-07-14       Impact factor: 91.245

3.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.

Authors:  Jennifer M Dan; Jose Mateus; Yu Kato; Kathryn M Hastie; Esther Dawen Yu; Caterina E Faliti; Alba Grifoni; Sydney I Ramirez; Sonya Haupt; April Frazier; Catherine Nakao; Vamseedhar Rayaprolu; Stephen A Rawlings; Bjoern Peters; Florian Krammer; Viviana Simon; Erica Ollmann Saphire; Davey M Smith; Daniela Weiskopf; Alessandro Sette; Shane Crotty
Journal:  Science       Date:  2021-01-06       Impact factor: 47.728

4.  Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.

Authors:  Alicia T Widge; Nadine G Rouphael; Lisa A Jackson; Evan J Anderson; Paul C Roberts; Mamodikoe Makhene; James D Chappell; Mark R Denison; Laura J Stevens; Andrea J Pruijssers; Adrian B McDermott; Britta Flach; Bob C Lin; Nicole A Doria-Rose; Sijy O'Dell; Stephen D Schmidt; Kathleen M Neuzil; Hamilton Bennett; Brett Leav; Mat Makowski; Jim Albert; Kaitlyn Cross; Venkata-Viswanadh Edara; Katharine Floyd; Mehul S Suthar; Wendy Buchanan; Catherine J Luke; Julie E Ledgerwood; John R Mascola; Barney S Graham; John H Beigel
Journal:  N Engl J Med       Date:  2020-12-03       Impact factor: 91.245

5.  Neutralizing Activity of BNT162b2-Elicited Serum.

Authors:  Yang Liu; Jianying Liu; Hongjie Xia; Xianwen Zhang; Camila R Fontes-Garfias; Kena A Swanson; Hui Cai; Ritu Sarkar; Wei Chen; Mark Cutler; David Cooper; Scott C Weaver; Alexander Muik; Ugur Sahin; Kathrin U Jansen; Xuping Xie; Philip R Dormitzer; Pei-Yong Shi
Journal:  N Engl J Med       Date:  2021-03-08       Impact factor: 91.245

6.  Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients.

Authors:  Mehul S Suthar; Matthew G Zimmerman; Robert C Kauffman; Grace Mantus; Susanne L Linderman; William H Hudson; Abigail Vanderheiden; Lindsay Nyhoff; Carl W Davis; Oluwaseyi Adekunle; Maurizio Affer; Melanie Sherman; Stacian Reynolds; Hans P Verkerke; David N Alter; Jeannette Guarner; Janetta Bryksin; Michael C Horwath; Connie M Arthur; Natia Saakadze; Geoffrey H Smith; Srilatha Edupuganti; Erin M Scherer; Kieffer Hellmeister; Andrew Cheng; Juliet A Morales; Andrew S Neish; Sean R Stowell; Filipp Frank; Eric Ortlund; Evan J Anderson; Vineet D Menachery; Nadine Rouphael; Aneesh K Mehta; David S Stephens; Rafi Ahmed; John D Roback; Jens Wrammert
Journal:  Cell Rep Med       Date:  2020-06-08
  6 in total
  51 in total

1.  SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63.

Authors:  Bezawit A Woldemeskel; Caroline C Garliss; Joel N Blankson
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 14.808

2.  Neutralizing antibodies levels are increased in individuals with heterologous vaccination and hybrid immunity with Ad5-nCoV in the north of Mexico.

Authors:  Karla Cervantes-Luevano; Astrid N Espino-Vazquez; Gonzalo Flores-Acosta; Johanna Bernaldez-Sarabia; Olivia Cabanillas-Bernal; Jahaziel Gasperin-Bulbarela; Ricardo Gonzalez-Sanchez; Andreu Comas-Garcia; Alexei F Licea-Navarro
Journal:  PLoS One       Date:  2022-06-24       Impact factor: 3.752

3.  Structural basis of Omicron immune evasion: A comparative computational study.

Authors:  Darshan Contractor; Christoph Globisch; Shiv Swaroop; Alok Jain
Journal:  Comput Biol Med       Date:  2022-06-20       Impact factor: 6.698

4.  Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease.

Authors:  Antonius T Otten; Arno R Bourgonje; Petra P Horinga; Hedwig H van der Meulen; Eleonora A M Festen; Hendrik M van Dullemen; Rinse K Weersma; Coretta C van Leer-Buter; Gerard Dijkstra; Marijn C Visschedijk
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

5.  SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies.

Authors:  Daniele Focosi; Marco Tuccori; Andreina Baj; Fabrizio Maggi
Journal:  Viruses       Date:  2021-06-23       Impact factor: 5.048

6.  Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy.

Authors:  T Alp Ikizler; P Toby Coates; Brad H Rovin; Pierre Ronco
Journal:  Kidney Int       Date:  2021-04-20       Impact factor: 10.612

7.  Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617.

Authors:  Lei Peng; Yingxia Hu; Madeleine C Mankowski; Ping Ren; Rita E Chen; Jin Wei; Min Zhao; Tongqing Li; Therese Tripler; Lupeng Ye; Ryan D Chow; Zhenhao Fang; Chunxiang Wu; Matthew B Dong; Matthew Cook; Guilin Wang; Paul Clark; Bryce Nelson; Daryl Klein; Richard Sutton; Michael S Diamond; Craig B Wilen; Yong Xiong; Sidi Chen
Journal:  bioRxiv       Date:  2021-12-24

8.  Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants.

Authors:  Amarendra Pegu; Sarah O'Connell; Stephen D Schmidt; Sijy O'Dell; Chloe A Talana; Lilin Lai; Jim Albert; Evan Anderson; Hamilton Bennett; Kizzmekia S Corbett; Britta Flach; Lisa Jackson; Brett Leav; Julie E Ledgerwood; Catherine J Luke; Mat Makowski; Paul C Roberts; Mario Roederer; Paulina A Rebolledo; Christina A Rostad; Nadine G Rouphael; Wei Shi; Lingshu Wang; Alicia T Widge; Eun Sung Yang; John H Beigel; Barney S Graham; John R Mascola; Mehul S Suthar; Adrian McDermott; Nicole A Doria-Rose
Journal:  bioRxiv       Date:  2021-05-16

9.  One year later: SARS-CoV-2 immune response and vaccination of healthcare workers post-infection.

Authors:  Chloé Dimeglio; Fabrice Herin; Marcel Miedougé; Isabelle Da-Silva; Marion Porcheron; Guillaume Martin-Blondel; Jean-Marc Soulat; Jacques Izopet
Journal:  J Infect       Date:  2021-06-18       Impact factor: 38.637

10.  COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now-New Hopes?

Authors:  Jean Jacques Vanden Eynde
Journal:  Pharmaceuticals (Basel)       Date:  2021-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.